ClinicalTrials.gg
Active, not recruitingNCT04513444HYPNOMUSEUpdated Sep 21, 2026

Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy

A Phase 2 interventional study of Relaxation with music listening and medical hypnosis during radiotherapy treatment: and Relaxation with music listening during radiotherapy treatment: in Solid Tumor, sponsored by Institut Claudius Regaud. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Institut Claudius Regaud · Phase 2, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This phase II, randomized, non-comparative and monocentric study aims to evaluate the interest of medical hypnosis in the management of anxiety in patients who are moderately anxious, anxious or very anxious during their radiotherapy treatment.

45 patients will be randomized into the following arms:

  • Arm A (standard): relaxation with music listening during radiotherapy treatment
  • Arm B (experimental): relaxation with music listening and hypnosis during radiotherapy treatment

For the study each patient will be followed during 2 months.

02

Conditions studied

  • Solid Tumor

Browse trials for

Keywords

  • Solid Tumor
  • Radiotherapy
  • Hypnosis
  • Anxiety
  • Music listening
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's planned enrollment of 45 is below the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Institut Claudius Regaud is the lead sponsor of 117 studies on the registry; 32 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years at the time of enrollment into the study.
  2. Patient with localized or solid malignant tumor.
  3. Patient being followed for the cancer pathology at IUCT-O and to receive, for the first time in the follow-up, treatment by radiotherapy (radiotherapy treatment should not have been initiated prior to inclusion in the study).
  4. Patient for whom radiotherapy treatment includes at least 15 sessions of radiation therapy.
  5. Patient defined as moderately anxious, anxious or very anxious after completing the STAI-Y self-assessment questionnaire (i.e. ≥ 46 score at inclusion).
  6. patient ≤ 2.
  7. Patient who signed prior to inclusion in the study and prior to any specific study procedures.
  8. Patient affiliated to a Social Health Insurance in France.

Exclusion criteria

Exclusion Criteria:

  1. Patient doesn't understand the French language.
  2. Patient with psychiatric disorders requiring antidepressant or antipsychotic treatment.
  3. Patient with hearing problems.
  4. Pregnant or breastfeeding women.
  5. Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol.
  6. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Other
    Standard arm (A): music listening therapy

    Other: Relaxation with music listening during radiotherapy treatment:

  • Experimental
    Experimental arm (B): music listening and hypnosis therapy

    Other: Relaxation with music listening and medical hypnosis during radiotherapy treatment:

Interventions

  • OtherRelaxation with music listening and medical hypnosis during radiotherapy treatment:

    * Music listening (According to the patient's wishes), * Hypnosis sessions with the hypnotherapist during the 1st, 2nd and 3rd radiotherapy session, * Self-hypnosis during the 4th and 5th radiotherapy session, * Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations.

  • OtherRelaxation with music listening during radiotherapy treatment:

    * Music listening (According to the patient's wishes), * Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations.

06

What researchers measure

Primary outcomes

  1. Rate of patients with at least a 10-point decrease in anxiety score (evolution between the baseline and the 6th and last radiotherapy session)

    Anxiety will be assessed using the STAI-Y questionnaire (Spielberger State-Trait Anxiety Inventory - State Anxiety form).

    Time frame: 2 months for each patient

Secondary outcomes

  1. Anxiety assessed using a numerical scale from 0 to 10 (0 being "not at all anxious" and 10 being "extremely anxious")

    Time frame: 2 months for each patient

  2. Quality of life assessed using the EORTC (European Organization for Research and Treatment of Cancer) Quality of life questionnaire (QLQ-C30).

    Changes in quality of life from baseline will be assessed in the classroom according to the recommendations of the literature (Osoba, JCO).

    Time frame: 2 months for each patient

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Nov 2026, 71 months after the start.

Of 81 non-industry phase 2 interventional studies under Anxiety Disorders, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's planned 71 months is above that.

Counting every sponsor, half of 96 studies reached it within 35 months; a quarter within 18 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 14, 2020
StartActual
Dec 7, 2020
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04513444
Responsible party
Sponsor
First posted
Aug 14, 2020
Start date
Dec 7, 2020
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Sep 21, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion